Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have received a consensus recommendation of “Hold” from the eight analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $66.00.
Several equities research analysts recently weighed in on the company. Robert W. Baird reaffirmed a “sell” rating and set a $24.00 price target on shares of Vir Biotechnology in a report on Friday, December 25th. The Goldman Sachs Group increased their price target on Vir Biotechnology from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, March 3rd. JPMorgan Chase & Co. cut Vir Biotechnology from a “neutral” rating to an “underweight” rating and set a $30.00 price objective for the company. in a research report on Wednesday, January 27th. Zacks Investment Research upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, HC Wainwright raised their price target on Vir Biotechnology from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, March 15th.
Shares of NASDAQ VIR traded down $0.46 during mid-day trading on Monday, hitting $45.09. 3,803 shares of the company were exchanged, compared to its average volume of 1,881,857. The stock has a 50 day simple moving average of $55.45 and a 200-day simple moving average of $40.81. Vir Biotechnology has a 1-year low of $25.31 and a 1-year high of $141.01. The firm has a market cap of $5.76 billion, a price-to-earnings ratio of -19.30 and a beta of -0.99.
In related news, EVP Herbert Virgin sold 31,300 shares of Vir Biotechnology stock in a transaction dated Tuesday, January 26th. The stock was sold at an average price of $48.17, for a total transaction of $1,507,721.00. Following the completion of the sale, the executive vice president now owns 64,500 shares in the company, valued at approximately $3,106,965. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jay Parrish sold 6,944 shares of Vir Biotechnology stock in a transaction dated Monday, February 1st. The stock was sold at an average price of $69.91, for a total value of $485,455.04. Following the sale, the insider now owns 224,536 shares of the company’s stock, valued at approximately $15,697,311.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,719 shares of company stock valued at $3,544,337. 37.20% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its stake in Vir Biotechnology by 2.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 9,870 shares of the company’s stock worth $264,000 after buying an additional 274 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Vir Biotechnology by 11.0% in the 3rd quarter. Victory Capital Management Inc. now owns 9,898 shares of the company’s stock valued at $340,000 after purchasing an additional 977 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in shares of Vir Biotechnology by 1.6% during the 4th quarter. State of Wisconsin Investment Board now owns 75,500 shares of the company’s stock valued at $2,022,000 after buying an additional 1,200 shares during the period. ProShare Advisors LLC raised its holdings in shares of Vir Biotechnology by 19.6% during the 3rd quarter. ProShare Advisors LLC now owns 7,685 shares of the company’s stock valued at $264,000 after buying an additional 1,259 shares during the period. Finally, Profund Advisors LLC raised its holdings in shares of Vir Biotechnology by 10.6% during the 4th quarter. Profund Advisors LLC now owns 14,379 shares of the company’s stock valued at $385,000 after buying an additional 1,377 shares during the period. Hedge funds and other institutional investors own 54.49% of the company’s stock.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis.
Featured Article: What is the return on assets (ROA) ratio?
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.